FDA lets Lilly cite Jardiance heart data, shares jump
(Reuters) - U.S regulators said on Friday they would allow Eli Lilly and Co to state that its diabetes drug Jardiance reduces risk of death from heart problems, lifting company shares almost 3 percent and potentially giving a strong boost to the drug's future sales. (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Empagliflozin Wins CV Prevention Indication
(MedPage Today) -- FDA approves claim that SGLT2 inhibitor reduces cardiovascular death risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 2, 2016 Category: Cardiology Source Type: news
Jardiance Wins CV Prevention Indication
(MedPage Today) -- FDA approves claim that diabetes drug reduces cardiovascular death risk (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 2, 2016 Category: American Health Source Type: news
FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes
The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 2, 2016 Category: American Health Source Type: news
FDA Approves Jardiance (empagliflozin) to Reduce Cardiovascular Death in Adults with Type 2 Diabetes
December 2, 2016 -- The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 2, 2016 Category: Drugs & Pharmacology Source Type: news
Empagliflozin cost effective for T2DM, reduces CV event rate
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news
Jardiance ® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 12, 2016 Category: Research Source Type: news
EMPA-REG: Good News for Kidneys, Too EMPA-REG: Good News for Kidneys, Too
The positive effects of empagliflozin on renal disease are discussed by Dr Christoph Wanner, one of the lead authors of the EMPA-REG OUTCOME trial.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
New Data on Empagliflozin in Treating Diabetic Kidney Disease New Data on Empagliflozin in Treating Diabetic Kidney Disease
Dr Desai discusses a new study exploring the long-term renal effects of empagliflozin and whether it could protect kidney function in patients with diabetes and chronic kidney disease.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2016 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news
Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG
In a clinical-trial update, researchers look into empagliflozin effects on type 2 diabetes patients who have heart failure at study baseline, incident heart failure during the trial, or not at all.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news
Synjardy (Empagliflozin and Metformin Hydrochloride Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2016 Category: Drugs & Pharmacology Source Type: news
Jardiance < sup > ® < /sup > (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Type 2 Diabetes: CHMP recommends empagliflozin* for approval
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
New Jardiance < sup > ® < /sup > (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
